Dr Edward Chow, PI at CSI Singapore, in collaboration with Professor Dean Ho of the UCLA School of Dentistry, has developed an innovative method to overcome multidrug chemoresistance in leukemia by synthesising nanodiamonds and daunorubicin. Their findings have been published in Nanomedicine: Nanotechnology, Biology and Medicine in September 2013.
For the first time, it has been discovered that binding the surfaces of nanodiamonds together with Daunorubicin, a drug commonly used to treat leukemia, greatly increases efficacy in the treatment of leukemia. Dr Chow’s breakthrough addresses the common issue of chemoresistance, or the resistance of cancer cells to chemotherapeutics, by utilizing the biocompatibility and non-invasive features of nanodiamonds to optimally deliver the necessary drugs to cancer cells without being pumped out. The tiny nanodiamond particles are then easily released by the body without causing any side effects.
While further tests and evaluations are conducted by the researchers, this innovative use of nanodiamonds offers great promise as therapeutic vehicles for leukemia and potentially for other disease models. Further reading